Bevacizumab in first-line treatment of metastatic breast cancer

被引：0
|
作者：
Miles, David [1 ]
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
来源：
DRUGS | 2007年 / 67卷 / 12期
关键词：
D O I：
10.2165/00003495-200767120-00010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：1800 / 1800
页数：1
相关论文
共 50 条
  • [21] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [22] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [23] Paclitaxel with bevacizumab (PB) as first-line therapy for metastatic breast cancer: Our experience
    Salesi, N.
    Colonna, M.
    Di Cocco, B.
    Moscato, M.
    Calogero, A.
    Pacini, L.
    Veltri, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] MicroRNAs correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer
    Gampenrieder, Simon P.
    Hamacher, Frank
    Rinnerthaler, Gabriel
    Hufnagl, Clemens
    Hackl, Hubert
    Romeder, Franz
    Muss, Claudia
    Hauser-Kronbeger, Cornelia
    Mlineritsch, Brigitte
    Greil, Richard
    [J]. CANCER RESEARCH, 2015, 75
  • [25] Bevacizumab as first-line therapy for advanced breast cancer
    Bartsch, R.
    de Vries, C.
    Foedermayr, M.
    Mader, R. M.
    Huber, M.
    Bago-Horvath, Z.
    Pluschnig, U.
    Steger, G. G.
    Dubsky, P.
    Fitzal, F.
    Schreil, G.
    Zielinski, C. C.
    Gampenrieder, S. P.
    Ziebermayr, R.
    [J]. ONKOLOGIE, 2010, 33 : 16 - 16
  • [26] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [27] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Alberto J. Montero
    Kiran Avancha
    Stefan Glück
    Gilberto Lopes
    [J]. Breast Cancer Research and Treatment, 2012, 132 : 747 - 751
  • [28] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Montero, Alberto J.
    Avancha, Kiran
    Glueck, Stefan
    Lopes, Gilberto
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 747 - 751
  • [29] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis
    Sun, Z-W
    Lan, X-Y
    Kong, F-L
    Gao, Y-Y
    Li, S.
    Xi, Y-L
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (17) : 5365 - 5373
12345